Last edition
News about "ArkBio"
ArkBio's AK0406 Influenza Prophylaxis Drug Receives China IND Approval
ArkBio has secured China IND approval for AK0406, a long-acting antiviral Fc conjugate for influenza prophylaxis, marking the first influenza AFC candidate to enter clinical development in China.
ArkBio | 14/08/2026 | By News Bureau
ArkBio Receives US FDA IND Clearance for AK3280 in Idiopathic Pulmonary Fibrosis
FDA clears ArkBio’s IND application for AK3280, enabling a Phase II proof-of-concept trial in the US to evaluate the novel anti-fibrotic therapy in patients with idiopathic pulmonary fibrosis.
ArkBio | 12/02/2026 | By News Bureau | 180
China Approves Azstarys for ADHD Treatment
ArkBio secures NMPA nod for once-daily ADHD treatment in China.
ArkBio | 06/01/2026 | By News Bureau | 526
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy